IMS 2025 | How does linvoseltamab compare with other bispecific antibodies in multiple myeloma?

Linvoseltamab is now the new kid on the block and in the myeloma world, you know we always say you’re never supposed to do cross-trial comparisons, but we also have a kind of our standard operating procedure, which is you state that and you take a deep breath in, and then you do the cross-trial comparisons. So linvoseltamab has one of the highest response rates, around 71%, which is really, really impressive, and it has probably the lowest CRS rate, in the mid-40s. So overall, it’s extremely well tolerated. Because it’s intravenous as opposed to the others that are subcutaneous, the time to CRS is much, much shorter. So we’re actually planning to roll this out with prophylactic tocilizumab, which will likely result in record low rates of CRS across the board. In addition, there’s been a variety of ways to administer these drugs in the inpatient and outpatient setting. The FDA label for linvoseltamab mentions 24-hour admission for cycle 1, day 1, and cycle 1, day 8, meaning overall less time in the hospital for patients. And overall, we’re trying to improve that. The other great thing is that it has built-in monthly dosing. So in the LINKER-MM1 study, patients who were at least 24 weeks into therapy in a VGPR or better were transitioned to monthly dosing. So again, really trying to find those strategies to not only bring the disease down, but provide long-term reasonable control of disease without causing harm to the patient.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.